FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783004697> ?p ?o ?g. }

• W2783004697 endingPage "243" @default.
• W2783004697 startingPage "233" @default.
• W2783004697 abstract "The relative bioavailability of lanabecestat administered as 2 tablet formulations versus an oral solution was investigated. This phase 1 single-center, open-label, randomized, 3-period crossover study involved healthy male and nonfertile female subjects aged 18-55 years (NCT02039180). Subjects received a single 50-mg lanabecestat dose as solution, tablet A, or tablet B on day 1 of each crossover period; 14 of 16 subjects completed the study. Relative bioavailability based on plasma lanabecestat AUC0-∞ (area under the plasma drug concentration-time curve from zero to infinity) geometric mean ratio versus oral solution (primary variable) was: tablet A, 1.052 (90% confidence interval [CI], 1.001-1.106); tablet B, 1.040 (0.989-1.093). These 90%CIs for geometric mean ratios are within accepted standard bioequivalence boundaries for all other pharmacokinetic (PK) parameters for both lanabecestat and metabolite (AZ13569724). All 3 formulations had similar plasma lanabecestat concentration-time profiles. Six adverse events were reported by 6 subjects (37.5%, all mild). GastroPlus modeling predicted a negligible impact of gastric pH changes on systemic PK (up to pH 7.4). Both tablet formulations fall within standard accepted bioequivalence criteria versus the oral solution. A single 50-mg lanabecestat dose was well tolerated as a solution or tablet formulation in this population." @default.
• W2783004697 created "2018-01-26" @default.
• W2783004697 creator A5001490313 @default.
• W2783004697 creator A5004476337 @default.
• W2783004697 creator A5006406925 @default.
• W2783004697 creator A5008652313 @default.
• W2783004697 creator A5011685816 @default.
• W2783004697 creator A5029876363 @default.
• W2783004697 creator A5065200734 @default.
• W2783004697 creator A5091559601 @default.
• W2783004697 date "2018-01-10" @default.
• W2783004697 modified "2023-10-14" @default.
• W2783004697 title "Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics" @default.
• W2783004697 cites W1004380294 @default.
• W2783004697 cites W115494979 @default.
• W2783004697 cites W1556033735 @default.
• W2783004697 cites W188995301 @default.
• W2783004697 cites W1964267627 @default.
• W2783004697 cites W1977416146 @default.
• W2783004697 cites W1981066923 @default.
• W2783004697 cites W1986309965 @default.
• W2783004697 cites W1993426606 @default.
• W2783004697 cites W2008286529 @default.
• W2783004697 cites W2029156005 @default.
• W2783004697 cites W2030641075 @default.
• W2783004697 cites W2041573170 @default.
• W2783004697 cites W2056414888 @default.
• W2783004697 cites W2082429191 @default.
• W2783004697 cites W2096410114 @default.
• W2783004697 cites W2103549354 @default.
• W2783004697 cites W2113033841 @default.
• W2783004697 cites W2124074440 @default.
• W2783004697 cites W2129495914 @default.
• W2783004697 cites W2150812630 @default.
• W2783004697 cites W2154755614 @default.
• W2783004697 cites W2163719308 @default.
• W2783004697 cites W2166109990 @default.
• W2783004697 cites W2258663952 @default.
• W2783004697 cites W2497876629 @default.
• W2783004697 cites W2532056566 @default.
• W2783004697 cites W2609217637 @default.
• W2783004697 cites W2746562707 @default.
• W2783004697 cites W2949891624 @default.
• W2783004697 cites W4292528167 @default.
• W2783004697 cites W789332891 @default.
• W2783004697 doi "https://doi.org/10.1002/cpdd.422" @default.
• W2783004697 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5947295" @default.
• W2783004697 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29319935" @default.
• W2783004697 hasPublicationYear "2018" @default.
• W2783004697 type Work @default.
• W2783004697 sameAs 2783004697 @default.
• W2783004697 citedByCount "9" @default.
• W2783004697 countsByYear W27830046972019 @default.
• W2783004697 countsByYear W27830046972020 @default.
• W2783004697 countsByYear W27830046972021 @default.
• W2783004697 countsByYear W27830046972022 @default.
• W2783004697 countsByYear W27830046972023 @default.
• W2783004697 crossrefType "journal-article" @default.
• W2783004697 hasAuthorship W2783004697A5001490313 @default.
• W2783004697 hasAuthorship W2783004697A5004476337 @default.
• W2783004697 hasAuthorship W2783004697A5006406925 @default.
• W2783004697 hasAuthorship W2783004697A5008652313 @default.
• W2783004697 hasAuthorship W2783004697A5011685816 @default.
• W2783004697 hasAuthorship W2783004697A5029876363 @default.
• W2783004697 hasAuthorship W2783004697A5065200734 @default.
• W2783004697 hasAuthorship W2783004697A5091559601 @default.
• W2783004697 hasBestOaLocation W27830046971 @default.
• W2783004697 hasConcept C105795698 @default.
• W2783004697 hasConcept C112705442 @default.
• W2783004697 hasConcept C126322002 @default.
• W2783004697 hasConcept C142724271 @default.
• W2783004697 hasConcept C181389837 @default.
• W2783004697 hasConcept C197934379 @default.
• W2783004697 hasConcept C204787440 @default.
• W2783004697 hasConcept C27081682 @default.
• W2783004697 hasConcept C2777056448 @default.
• W2783004697 hasConcept C33923547 @default.
• W2783004697 hasConcept C40222840 @default.
• W2783004697 hasConcept C42404028 @default.
• W2783004697 hasConcept C44249647 @default.
• W2783004697 hasConcept C71924100 @default.
• W2783004697 hasConcept C77281830 @default.
• W2783004697 hasConcept C87813604 @default.
• W2783004697 hasConcept C98274493 @default.
• W2783004697 hasConceptScore W2783004697C105795698 @default.
• W2783004697 hasConceptScore W2783004697C112705442 @default.
• W2783004697 hasConceptScore W2783004697C126322002 @default.
• W2783004697 hasConceptScore W2783004697C142724271 @default.
• W2783004697 hasConceptScore W2783004697C181389837 @default.
• W2783004697 hasConceptScore W2783004697C197934379 @default.
• W2783004697 hasConceptScore W2783004697C204787440 @default.
• W2783004697 hasConceptScore W2783004697C27081682 @default.
• W2783004697 hasConceptScore W2783004697C2777056448 @default.
• W2783004697 hasConceptScore W2783004697C33923547 @default.
• W2783004697 hasConceptScore W2783004697C40222840 @default.
• W2783004697 hasConceptScore W2783004697C42404028 @default.
• W2783004697 hasConceptScore W2783004697C44249647 @default.
• W2783004697 hasConceptScore W2783004697C71924100 @default.

• next